ARN2966 - Moligand™, 10 mM in DMSO , CAS No.102212-26-0

CAS: 102212-26-0 Cat. No.: A1498743 Formule: C12H12N2O Poids moléculaire: 200.24 Numéro CE: 109-896-9
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10 mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
USA
Allemagne (EU)*
Prix
Qté
1ml
A1498743-1ml
Sur commande · 8–12 semaines
104,90$US
Enter a quantity for the sizes you want to add.

Vue d’ensemble

ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ. IC50 value: Target: AβThis potent post-transcriptional modulation of APP expression differs from other mechanisms such as inhibition of secretases. Secretase inhibitors have been pursued as disease modifying strategies by a number of pharmaceutical firms but they have encountered numerous setbacks during clinical development. ARN2966 is non toxic, orally absorbable, blood-brain-barrier penetrable, and effective in vitro and in vivo.

Spécifications

Spécifications et pureté
Moligand™, 10 mM in DMSO
Conditions de stockage de stockage
Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Grade
Moligand™
Type d'action
INHIBITOR
Noms et identifiants
Isomères SMILES
C1=CC=C(C(=C1)NCC2=CC=CC=N2)O
Poids moléculaire
200.24

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Avis

Avis des clients

Application Protocols

No vendor-tested biological or analytical protocols are specified for ARN2966 in this listing.

General starting points for screening compounds (not item-specific)

  • Stock preparation: Dissolve in anhydrous DMSO to a convenient concentration (e.g., 10–50 mM) after verifying solubility. Vortex and, if needed, sonicate briefly. Pass through a 0.22 µm PTFE filter if particles persist.
  • Working solutions: Dilute into assay buffer immediately before use to minimize precipitation. Keep final DMSO at assay-compatible levels.
  • Controls: Include vehicle controls at the same DMSO percentage; run concentration-response curves with appropriate replicates.
  • Storage of stocks: Aliquot to single-use vials/plates to avoid repeated freeze–thaw cycles.

Please validate all conditions in your assay system. For any item-specific instructions, consult the lot CoA/Spec Sheet.

Biological Roles

Item-specific biological target(s), mechanism(s) of action, and pathway involvement are not provided for ARN2966 in this listing.

General considerations for library compounds (not item-specific)

  • Screening role: Small molecules in discovery libraries are used to probe biological systems, identify hits, and generate structure–activity relationships (SAR). Their biological roles emerge from assay results rather than prior annotation.
  • Phenotypic vs target-based: Compounds may be evaluated in cell-based phenotypic assays or biochemical target-based assays. Follow-up deconvolution and orthogonal assays are required to confirm specificity and rule out assay interference.
  • Assay interference risk: Without full annotation, evaluate for pan-assay interference structures (PAINS), redox activity, aggregation, autofluorescence, or metal chelation using appropriate counter-screens.

Recommendations

  • Request structural information and any available prior art references before making mechanistic inferences.
  • Include cytotoxicity and selectivity counterscreens early to contextualize activity.

No medical/clinical claims are made. ARN2966 is supplied strictly for research use only.

Buffer Applications

Not typically applicable. ARN2966 is a small-molecule screening compound, not a buffering agent. It is generally dissolved in an appropriate solvent (commonly DMSO) and then diluted into existing biological buffers formulated for the assay.

Practical notes (general)

  • Maintain final DMSO (or other co-solvent) at assay-compatible levels to preserve buffer capacity and biological integrity.
  • Filter or centrifuge diluted samples if precipitation is observed upon addition to buffer.

For buffer formulation guidance, refer instead to established buffer systems (PBS, HEPES, Tris, etc.) appropriate to your assay; ARN2966 itself does not define a buffer system.

Green Alternatives

Because ARN2966 is a screening library compound and not a solvent or bulk reagent, “green alternatives” considerations focus on handling and solvent choices during use rather than replacing the compound itself.

Greener handling strategies (general; not item-specific)

  • Use minimal DMSO volumes and prepare higher-concentration stocks to reduce solvent waste; aliquot to limit freeze–thaw cycles and discard.
  • Consider MeOH/EtOH or water-miscible green co-solvents (where compatible with the assay) at low percentages to reduce DMSO dependence.
  • Employ micro-scale assays and 384/1536-well formats to minimize chemical usage.

Illustrative solvent comparison (general)

  • DMSO: High solvency, common for HTS; not inherently green but effective at low volumes.
  • Ethanol: Bio-friendly and renewable; lower solvency for hydrophobic chemotypes.
  • 2-MeTHF/CPME: Greener ethers for synthesis; typically not used for biological dilutions but useful for preparative steps if derivatization is undertaken.

Operational sustainability

  • Consolidate shipments on dry ice to reduce packaging waste.
  • Use reusable cold-chain materials where your facility permits.

Note: There is no substitute compound proposed here since ARN2966’s structure and function are not disclosed in this listing.

Pharmaceutical Uses

Not intended for pharmaceutical use. ARN2966 is supplied for research use only (screening, discovery chemistry, or analytical method development). No pharmacopeial status, excipient role, or GMP grade is indicated.

Context for discovery workflows (general; not item-specific)

  • Early discovery: Library members can serve as chemical starting points (“hits”) for medicinal chemistry optimization once structure and liabilities are understood.
  • Preformulation research: If advanced, solubility, stability, and polymorph screening may be explored under research conditions—only after full characterization and with appropriate controls.

Compliance note

  • This product is not for use in humans or animals, not for diagnostic procedures, and not for manufacturing or clinical applications. For any work beyond basic research, obtain appropriate grade and regulatory documentation.
Physical Properties

Item-specific properties (as supplied)

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point: Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • LogP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • Refractive index/UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/best practice for library compounds; not item-specific)

  • Solubilization strategy: Start with anhydrous DMSO stock solutions (e.g., 10–50 mM) after confirming solubility; for aqueous assays, dilute the DMSO stock into assay buffer keeping final DMSO ≤0.1–1% v/v as protocol allows.
  • Co-solvents: If aqueous precipitation occurs, consider small percentages of co-solvents (MeCN, ethanol) or surfactants compatible with the assay. Always verify compatibility.
  • pH effects: Weak acids/bases can show pH-dependent solubility; prepare buffers accordingly if ionization is known.

Important

  • Do not treat the above as specifications. For quantitative work (formulation, analytics), obtain the lot-specific CoA/SDS to access definitive physicochemical values.
Quality and Grades

Grade information

  • Supplied as Moligand: This denotes an Aladdin research-grade small-molecule library member intended for screening, ligand discovery, and cheminformatics workflows.

What Moligand typically implies (general; not item-specific unless stated on CoA)

  • Research-use only, not for human or veterinary use.
  • Lot-traceable packaging; each lot is accompanied by or can be provided with a Certificate of Analysis (CoA) detailing identity confirmation (e.g., spectroscopic or LC/MS report) and purity where available.
  • Form may be neat solid, film, or pre-dosed microplate/vial format suitable for high-throughput screening.

Not provided in the current listing (consult CoA/SDS)

  • Exact purity, residual solvent profile, water content, metal content, stabilizers, and UV characteristics: Not specified for this item; refer to CoA/Spec Sheet.

Practical implications

  • For screening: Verify concentration by weight or by quantitative NMR/UV as appropriate.
  • For hit-to-lead or medicinal chemistry: Obtain full characterization data and impurity profile before scale-up or biological interpretation.
  • If stabilizers or salts are present, they will be disclosed on the lot documentation; adjust molarity calculations accordingly.
Reaction and Applications

This product is supplied as a screening/ligand discovery compound. It is not primarily intended for use as a synthetic reagent. Item-specific reactivity or functional-group information is not provided.

Potential research applications (general; not item-specific)

  • High-throughput screening (HTS), fragment/lignad identification, or phenotypic assays where small-molecule modulators are evaluated.
  • Cheminformatics benchmarking, QSAR model building, and machine-learning studies using lot-confirmed structural data (request SDF/SMILES if available).
  • Analytical method development: LC/MS retention and ionization behavior characterization for library build-outs.

If synthetic derivatization is planned

  • Obtain the structure and functional-group map from the CoA/Spec Sheet before proposing transformations.
  • Standard medicinal chemistry workflows may include: selective functionalization for SAR, installation/removal of solubilizing groups, or prodrug exploration—only after full structural and stability disclosure.

Important

  • Without the disclosed structure, do not assume compatibility with named reactions, catalytic systems, or protection/deprotection regimes. Validate on milligram scale with appropriate controls.
Reaction Conditions

Not applicable in the usual sense. ARN2966 is not supplied as a reagent with defined reactivity, and no structure or functional groups are disclosed in this listing.

General notes if exploratory chemistry is attempted (not item-specific)

  • Solvent: Choose based on solubility and stability (e.g., anhydrous DMSO, DMF, MeCN, or toluene) after preliminary solubility screens.
  • Temperature: Begin with ambient conditions; escalate cautiously while monitoring for decomposition by TLC/LC-MS.
  • Atmosphere: Use inert gas (N2/Ar) if moisture/oxygen sensitivity is suspected from CoA/SDS or preliminary results.
  • Catalysts/bases/acids: Select only after mapping potential reactive sites; run small-scale screens to avoid destructive conditions.

Because item-specific reaction behavior is unknown, any conditions must be developed empirically and validated on milligram scale before scale-up.

Safety and Handling

GHS and hazard data for this specific item

  • Signal word: Not specified for this item; refer to SDS.
  • Hazard statements (H-phrases): Not specified for this item; refer to SDS.
  • GHS classification/pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (best practice for small-molecule libraries; not item-specific)

  • Handle in a chemical fume hood; avoid inhalation of dusts/aerosols and contact with skin/eyes.
  • PPE: Lab coat, nitrile gloves, and splash goggles as a minimum. Upgrade to double-gloving and face protection for bulk handling.
  • Incompatibilities: Unknown for this item; segregate from strong oxidizers/reducers and acids/bases until SDS confirms compatibility.
  • Hygiene: Wash thoroughly after handling; do not eat, drink, or smoke in work areas.

First-aid overview (follow institutional SOPs and SDS)

  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin contact: Wash with soap and water; remove contaminated clothing.
  • Eye contact: Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do; obtain medical advice.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.

Spill/fire

  • Small spills: Absorb with inert material; collect for disposal in labeled container.
  • Fire: Use CO2, dry chemical, or foam. Decomposition hazards unknown—firefighters should wear SCBA.

Always defer to the official SDS for ARN2966 for authoritative hazard, first-aid, and disposal information.

Solvent Selection

Item-specific solubility is not provided for ARN2966. The following guidance reflects common practices for screening compounds and should be validated experimentally.

Preferred primary solvent

  • DMSO (anhydrous) is the default solvent for preparing concentrated stocks of diverse small molecules due to broad solvency and assay compatibility at low percentages.

Secondary options (case-dependent)

  • Acetonitrile or ethanol for analytical dilutions and LC-compatible preparations.
  • DMF or NMP for challenging, highly lipophilic compounds (ensure assay compatibility and toxicity controls).
  • Aqueous buffers with co-solvent (0.1–1% DMSO or MeCN) after confirming the compound’s tolerance and avoiding precipitation.

Considerations

  • pH: Ionizable compounds may dissolve better when buffered ≥1 pH unit from pKa (if known). For unknowns, avoid extreme pH unless stability is characterized.
  • Adsorption: Minimize compound loss by using low-bind plastics or silanized glass for highly lipophilic compounds.
  • Light/oxygen sensitivity: If suspected based on class information from CoA/SDS, protect from light and use degassed solvents.

Quick comparison (general)

  • DMSO: Maximum solvency and stability; may inhibit some enzymes above 1%.
  • MeCN: Volatile, LC-MS friendly; lower solvency breadth than DMSO.
  • EtOH: Biologically tolerated in some assays; variable solubility for hydrophobes.

Always confirm solubility and stability of ARN2966 under your specific experimental conditions.

Storage and Reconstitution

Item-specific instructions

  • Storage conditions: Store at -80°C.
  • Shipping: Shipped with dry ice packs + cold packs to maintain cold chain.

Reconstitution and handling (general guidance; not item-specific)

  • Solvent: Use anhydrous DMSO as the primary solvent unless CoA indicates otherwise. Confirm solubility before preparing concentrated stocks.
  • Concentrated stocks: Prepare high-concentration stocks to minimize freeze–thaw; aliquot into low-bind tubes or plates. Clearly label concentration, solvent, lot, and date.
  • Freeze–thaw: Avoid repeated cycles. Thaw on ice or at room temperature briefly; refreeze promptly after use.
  • Light/air sensitivity: If the SDS or class information suggests sensitivity, work under inert gas and protect from light (amber vials, foil wrap).

Stability notes

  • Long-term stability, hydrate/solvate form, and solution stability are not specified for this item; refer to CoA/Spec Sheet.
  • Before critical experiments, verify integrity by LC/MS or analytical HPLC following storage.

Disposal

  • Dispose of unused solutions and wastes according to institutional and local regulations. Consult the SDS for compatible waste streams.
Structure and Identity

Overview for ARN2966 (SKU A1498743) as supplied in Aladdin’s Moligand small-molecule library format.

  • Product name: ARN2966
  • CAS: 102212-26-0
  • PubChem CID: 14936865
  • SKU: A1498743
  • Grade: Moligand
  • Category: Small molecules and compound libraries (research use only)

Item-specific identifiers

  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

  • Functional groups, ring systems, and stereochemistry: Not specified for this item; refer to CoA/Spec Sheet and SDS for definitive identity and hazards.

Notes

  • ARN2966 is provided as part of a screening/ligand discovery collection. If you require structural descriptors for computational work (QSAR/docking), request the SDF/SMILES from the lot-specific CoA or contact technical support to obtain structure disclosure subject to licensing terms.
Synthetic Utility

Primary purpose

  • ARN2966 is provided as a screening compound. Without disclosed structure or functional groups, it is not positioned as a general synthetic reagent.

If used in synthesis or derivatization (general guidance; not item-specific)

  • Obtain structural information from the CoA/Spec Sheet to identify reactive handles (heteroatoms, halogens, carbonyls, etc.).
  • Plan medicinal chemistry campaigns around identified liabilities (metabolic soft spots, hydrolysis-prone motifs) and physicochemical tuning (logD, pKa, TPSA) based on measured data.
  • Protecting group strategies, cross-couplings, or late-stage functionalization should be chosen only after confirming compatibility and stability profiles.

Analytical characterization

  • Use orthogonal methods (LC/MS, NMR, HRMS, purity by LC-UV/ELSD) to verify identity and purity of any derivatives prepared from ARN2966.

In summary, treat ARN2966 as a potential starting point for SAR once structural details are confirmed; do not assume any particular reactivity without disclosure.

Target Specificity

Not specified for this item; refer to CoA/Spec Sheet or contact technical support for any available target annotations. As listed, ARN2966 is a research library compound with no disclosed antigen/epitope or biological target specificity.

Foire aux questions

What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 102212-26-0, the molecular formula is C12H12N2O, and the molecular weight is 200.24 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Besoin d'aide pour choisir la qualité ?

Notre guide de sélection des qualités couvre la pureté, le statut du stabilisant et l'adéquation à l'application pour toutes les variantes de notre catalogue.

Voir le guide des qualités Moligand™ →

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.